Chargement des cours...
Prévisions
L'objectif de cours moyen des analystes est de 57,39 € (+1 535,04 %). La médiane est de 36,64 € (+943,87 %).
| Acheter |
5 |
| Conserver |
13 |
| Vendre |
2 |
Actualités Accéder au fil d'actualités
Tilray invests £50m in BrewDog to improve beers, pubs and working conditions
Tilray, which bought BrewDog in March for £33m after the brewer entered administration, is investing more than £50m to improve beer quality, reopen and upgrade selected bars, raise pay and improve working conditions. The company is upgrading the Aberdeenshire brewery, launching new beers, introducing US craft lines into BrewDog venues and considering further UK craft acquisitions. Administrators said creditors will not be repaid in full and crowdfunding shares were rendered worthless, though some investor benefits and supplier continuity have been maintained. » Plus sur theguardian.com
Tilray positioned to benefit if Trump advances marijuana rescheduling
A federal appeals court refused to pause the Biden administration's move to consider broader rescheduling of marijuana, keeping alive a proposal to reclassify cannabis to Schedule III. Schedule III would not legalize recreational use or interstate commerce but could ease research and expand medical opportunities that would help Tilray's international medical cannabis business. Tilray reported record fiscal 2026 revenue, sharply improved cash flow and near-elimination of net debt, and management sees U.S. rescheduling as a future growth opportunity. Legal challenges and timing remain uncertain, so potential investors should view rescheduling as upside rather than a guaranteed catalyst. » Plus sur finance.yahoo.com
Tilray Brands posts record fiscal 2026 revenue but shares fail to rally
Tilray Brands reported record fiscal 2026 revenue of about $915 million and an 11% rise in adjusted EBITDA to $61.1 million, with adjusted net income nearly doubling to $12.2 million. The results nonetheless missed sell-side forecasts and the company recorded a GAAP net loss of $49.6 million. Management guided to modest adjusted EBITDA growth for fiscal 2027 and has reduced debt largely through dilutive debt-for-equity swaps, while cannabis now represents only 29% of sales, leaving investors hesitant to drive the stock higher. » Plus sur finance.yahoo.com
Dividendes historiques Dividendes
Tous les indicateurs de dividendes Tous les indicateursDonnées financières de l'entreprise
| (EUR) | mai 2026 | |
|---|---|---|
| Chiffre d'affaires | 241,83 M | 10,93 % |
| Bénéfice brut | 72,39 M | 11,49 % |
| Bénéfice net | -42,55 M | 97,24 % |
| EBITDA | 12,75 M | 100,78 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 370,21 M € |
Nombre d'actions | 111,83 M |
Plus haut/bas sur 52 semaines | 20,48 € - 3,24 € |
| Dividendes | Non |
Bêta | 1,92 |
Ratio P/E | -2,81 |
Ratio PEG | -0,02 |
Ratio P/B | 0,26 |
Ratio P/S | 0,36 |
Profil de l'entreprise
Tilray Brands Inc. beschäftigt sich mit der Forschung, dem Anbau, der Produktion, dem Marketing und dem Vertrieb von medizinischen Cannabisprodukten. Das Unternehmen ist in fünf Segmenten tätig: Cannabis Business, Distribution Business, Beverage Alcohol Business, Wellness Business, und Business Under Development. Das Unternehmen bietet medizinische und für Erwachsene bestimmte Cannabisprodukte, pharmazeutische und Wellness-Produkte, alkoholische Getränke sowie hanfbasierte Lebensmittel und andere Wellness-Produkte an. Es bietet seine Produkte Einzelhändlern, Großhändlern, Patienten, Ärzten, Apotheken, Kliniken, Krankenhäusern, Regierungen und Forschern an. Das Unternehmen betreibt Tilray Medical, eine medizinische Plattform, die GMP-zertifizierte Blüten, Öle, Vapes, Esswaren und topische Produkte anbietet. Es hat Niederlassungen in Kanada, den Vereinigten Staaten, Europa, Australien, Neuseeland, Lateinamerika und international. Das Unternehmen war früher unter dem Namen Tilray, Inc. bekannt. Tilray Brands Inc. wurde im Jahr 2018 gegründet und hat seinen Hauptsitz in New York, New York.
| Nom | Tilray |
| PDG | Irwin David Simon |
| Siège social | Leamington,
on États-Unis |
| Site web | |
| Secteur | Santé |
| Industrie | Biotechnologie |
| Introduction en bourse | 19/07/2018 |
| Employés | 3 595 |
Symboles boursiers
| Bourse | Symbole |
|---|---|
NASDAQ | TLRY |
Toronto Stock Exchange | TLRY.TO |
XETRA | 2HQ.DE |
Frankfurt | 2HQ.F |
Düsseldorf | 2HQ.DU |
Hamburg | 2HQ.HM |
SIX | 2HQ.SW |
München | 2HQ.MU |
Wien | TLRY.VI |